Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Novartis AG (NVS) vs Visa Inc (V) Price & Performance

Novartis AGTrade

Price performance (Past 24H)

Key statistics

Novartis AG vs Visa Inc — how do they compare? Novartis AG trades at $152.61 (market cap $295.37B), while Visa Inc trades at $360.97 (market cap $671.74B). The key difference: Visa Inc is far larger — about 2.3× Novartis AG's market cap, and Novartis AG pays the higher dividend (3.07%). Which is the better fit depends on your goals.

NVSV
Market Cap
$295.37B$671.74B
Sector
HealthFinancials
52-Week High
$168.62$370.47
52-Week Low
$119.31$295.52
Enterprise Value
$336.69B$682.32B
Dividend Yield
3.07%0.74%
Volume
10,431,336

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novartis AG

Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.

The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.

Visa Inc

Visa (V) trades at $361.32, down 0.33% on the day, with a bearish technical signal but strong fundamentals. The stock shows consistent earnings beats, with Q2 2026 EPS of $3.32 exceeding the $3.23 estimate. Revenue grew to $40 billion in 2025, with a net income margin of 50.78%. Recent news highlights Visa's AI initiatives, such as Intelligent Commerce Connect, to enhance payment efficiency.

The outlook remains positive due to high analyst buy ratings (85.48%) and a consensus price target of $426.31, implying 18% upside. Risks include fintech competition and regulatory pressures, but Visa's robust cash flow and profitability support long-term growth potential for investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS

About Visa Inc

Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.

Read more on V